TheraCIM hR3 nimotuzumab: Phase II started

YM began a single-arm North American Phase II trial of nimotuzumab monotherapy in 44 pediatric patients. YM granted Japanese rights for nimotuzumab to Daiichi and European rights to Oncoscience. ...